Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 2/20 | 0.65 |
| ▸ | IL23R | Q5VWK5 | 6/20 | 0.62 |
| ▸ | CCKBR | P32239 | 2/20 | 0.59 |
| ▸ | GHSR | Q92847 | 2/20 | 0.59 |
| ▸ | MC4R | P32245 | 2/20 | 0.58 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357687 | 0.86 | KISS1R (0.62) | KISS1RMC4R | |
| SCHEMBL26006274 | 0.85 | KISS1R (0.64) | KISS1RGHSRMC4R | |
| SCHEMBL29359331 | 0.85 | KISS1R (0.64) | KISS1RGHSRMC4R | |
| SCHEMBL26006253 | 0.85 | KISS1R (0.64) | KISS1RGHSRMC4R | |
| SCHEMBL21146569 | 0.82 | IL23R (0.66) | IL23RMC4R | |
| SCHEMBL29527343 | 0.82 | NPY1R (0.70) | KISS1RCCKBRGHSRMC4RNPBWR1 | |
| SCHEMBL25767621 | 0.81 | MC4R (0.66) | KISS1RGHSRMC4RNPBWR1CXCR4 | |
| SCHEMBL29500559 | 0.80 | CCKBR (0.67) | KISS1RCCKBRGHSRNPBWR1 | |
| SCHEMBL30999649 | 0.80 | KISS1R (0.57) | KISS1RIL23RCCKBRNPBWR1 | |
| SCHEMBL29546807 | 0.79 | GHSR (0.90) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117083060-A | Topical patches for targeted siRNA nanocomposite delivery and gene therapy: composition, method for producing same, and use thereof | 南洋理工大学 | 2023-11-17 | — | — | CN | claimed |
| WO-2022159036-A1 | TOPICAL PATCH FOR TARGETED siRNA NANOPLEX DELIVERY AND GENE THERAPIES: COMPOSITION, METHOD OF MAKING AND USE THEREOF | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-07-28 | — | — | WO | claimed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | claimed |
| US-20250332298-A1 | PEPTIDE-COUPLED ALGINATE GELS COMPRISING RADIONUCLIDES | BLUE WAVE THERAPEUTICS GMBH (CH) | 2025-10-30 | — | — | US | disclosed |
| US-20250275931-A1 | TOPICAL PATCH COMPOSITION FOR TARGETED SIRNA NANOPLEX DELIVERY AND GENE THERAPIES AND METHOD OF MAKING AND USE THEREOF | National Skin Centre (Singapore) Pte Ltd (SG) | 2025-09-04 | — | — | US | disclosed |
| US-20240408247-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-12-12 | — | — | US | disclosed |
| US-20240285628-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2024-08-29 | — | — | US | disclosed |
| US-12059472-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-13 | — | — | US | disclosed |
| EP-4351654-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4351653-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-02-08 | — | — | US | disclosed |
| CN-114794099-A | Nitrogen-containing surfactants for use in agriculture | 诺力昂化学品国际有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2022159036-A1 | TOPICAL PATCH FOR TARGETED siRNA NANOPLEX DELIVERY AND GENE THERAPIES: COMPOSITION, METHOD OF MAKING AND USE THEREOF | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-07-28 | — | — | WO | disclosed |
| CN-109068645-B | Mixtures and compositions comprising a paenibacillus strain or fusaricidin and a chemical pesticide | 巴斯夫欧洲公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114599644-A | Nicotinamide compound and herbicide composition containing the same | 韩国化学研究院 | 2022-06-07 | — | — | CN | disclosed |
| CN-111801014-B | Fungicidal compositions of cloroxen | 巴斯夫农业公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-111771885-B | Pest control composition comprising novel iminopyridine derivatives | 株式会社MMAG | 2022-05-17 | — | — | CN | disclosed |
| CN-108366563-B | Herbicide mixture and preparation for potatoes | 阿达玛阿甘有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-110868861-B | Agricultural compositions | 萨卡帕·瓦达卡库塔 | 2022-03-15 | — | — | CN | disclosed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12059472-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | LGMN, BUB1B, KIF15 | KISS1R 2772/4885IL23R 4431/4885CCKBR 4555/4885 |
| US-20240408247-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | GRPR, SCTR, NPSR1 | KISS1R 1398/4885IL23R 505/4885CCKBR 244/4885 |
| US-20240285628-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | GRPR, SCTR, NPSR1 | KISS1R 1398/4885IL23R 505/4885CCKBR 244/4885 |
| US-20250332298-A1 | PEPTIDE-COUPLED ALGINATE GELS COMPRISING RADIONUCLIDES | ALG1, ALG3, GRPR | KISS1R 205/4885IL23R 891/4885CCKBR 178/4885 |
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BUB1B, KIF5B, TK1 | KISS1R 3755/4885IL23R 4668/4885CCKBR 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.